InMed Pharmaceuticals Inc. announced the completion of the previously disclosed merger between the Company and the privately held Mentari Therapeutics, Inc. The combined company will continue to operate under the name Mentari Therapeutics, Inc..
Immediately prior to the closing of the merger, the Company completed its redomestication from British Columbia, Canada to the State of Nevada, and pre-merger Mentari completed its previously announced private financings totaling approximately $490 million in gross proceeds. The proceeds include the conversion of $50.0 million of previously issued convertible notes, plus accrued interest thereon. Pursuant to the terms of the previously disclosed merger agreement, each outstanding share of pre-merger Mentari common stock was converted into the right to receive approximately 0.20065 shares of common stock of the combined company, as adjusted for the 1-for-10 reverse stock split of the Company's common shares effected on November 4, 2026.